| 1 Clinically important response (defined by study) |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 1.1 short term (up to 12 weeks) |
1 |
25 |
Risk Ratio (M‐H, Random, 95% CI) |
0.62 [0.12, 3.07] |
| 2 Global state: 1. CGI: Average endpoint CGI‐SI (high = poor) |
1 |
|
Mean Difference (IV, Random, 95% CI) |
Subtotals only |
| 2.1 short term (up to 12 weeks) |
1 |
25 |
Mean Difference (IV, Random, 95% CI) |
‐0.03 [‐0.92, 0.86] |
| 3 Mental state: 2a. General ‐ average endpoint score (BPRS total, high = poor) |
1 |
|
Mean Difference (IV, Random, 95% CI) |
Subtotals only |
| 3.1 short term (up to 12 weeks) |
1 |
25 |
Mean Difference (IV, Random, 95% CI) |
‐1.98 [‐12.96, 9.00] |
| 4 Mental state: 2b. Positive symptoms ‐ average endpoint score (BPRS positive sub‐score, high = poor) |
1 |
|
Mean Difference (IV, Random, 95% CI) |
Subtotals only |
| 4.1 short term (up to 12 weeks) |
1 |
25 |
Mean Difference (IV, Random, 95% CI) |
‐13.61 [‐20.77, ‐6.45] |
| 5 Mental state: 2c. Negative symptoms ‐ average endpoint score (BPRS negative sub‐score, high = poor) |
1 |
|
Mean Difference (IV, Random, 95% CI) |
Subtotals only |
| 5.1 short term (up to 12 weeks) |
1 |
24 |
Mean Difference (IV, Random, 95% CI) |
‐0.11 [‐2.27, 2.05] |
| 6 Mental state: 2d. Anxiety/depression symptoms ‐ average endpoint score (BPRS anxiety/depression sub‐score, high score = poor) |
|
|
Other data |
No numeric data |
| 6.1 short term (up to 12 weeks) |
|
|
Other data |
No numeric data |
| 7 Mental state: 2e. Hostility symptoms ‐ average endpoint score (BPRS hostility sub‐score, high = poor) |
1 |
|
Mean Difference (IV, Random, 95% CI) |
Subtotals only |
| 7.1 short term (up to 12 weeks) |
1 |
24 |
Mean Difference (IV, Random, 95% CI) |
0.79 [‐2.45, 4.03] |
| 8 Mental state: 2f. Activation symptoms ‐ average endpoint score (BPRS activation sub‐score, high = poor) |
|
|
Other data |
No numeric data |
| 8.1 short term (up to 12 weeks) |
|
|
Other data |
No numeric data |
| 9 Adverse effects: 1. Anticholinergic effect |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 9.1 dry mouth ‐ short term (up to 12 weeks) |
1 |
24 |
Risk Ratio (M‐H, Random, 95% CI) |
1.0 [0.17, 5.98] |
| 9.2 blurred vision ‐ short term (up to 12 weeks) |
1 |
24 |
Risk Ratio (M‐H, Random, 95% CI) |
1.0 [0.17, 5.98] |
| 9.3 urinary hesitancy ‐ short term (up to 12 weeks) |
1 |
24 |
Risk Ratio (M‐H, Random, 95% CI) |
1.0 [0.17, 5.98] |
| 10 Adverse effects: 2. Central nervous system |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 10.1 anxiety ‐ short term (up to 12 weeks) |
1 |
24 |
Risk Ratio (M‐H, Random, 95% CI) |
1.0 [0.07, 14.21] |
| 10.2 headache ‐ short term (up to 12 weeks) |
1 |
24 |
Risk Ratio (M‐H, Random, 95% CI) |
1.0 [0.39, 2.58] |
| 10.3 insomnia ‐ short term (up to 12 weeks) |
1 |
24 |
Risk Ratio (M‐H, Random, 95% CI) |
1.67 [0.51, 5.46] |
| 10.4 lethargy ‐ short term (up to 12 weeks) |
1 |
24 |
Risk Ratio (M‐H, Random, 95% CI) |
1.5 [0.30, 7.43] |
| 10.5 somnolence ‐ short term (up to 12 weeks) |
1 |
24 |
Risk Ratio (M‐H, Random, 95% CI) |
1.33 [0.38, 4.72] |
| 11 Adverse effects: 3. Gastrointerstinal adverse effects |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 11.1 constipation ‐ short term (up to 12 weeks) |
1 |
24 |
Risk Ratio (M‐H, Random, 95% CI) |
1.0 [0.32, 3.10] |
| 11.2 diarrhoea ‐ short term (up to 12 weeks) |
1 |
24 |
Risk Ratio (M‐H, Random, 95% CI) |
0.2 [0.01, 3.77] |
| 11.3 dyspepsia ‐ short term (up to 12 weeks) |
1 |
24 |
Risk Ratio (M‐H, Random, 95% CI) |
3.0 [0.36, 24.92] |
| 11.4 nausea/ vomiting ‐ short term (up to 12 weeks) |
1 |
24 |
Risk Ratio (M‐H, Random, 95% CI) |
2.0 [0.21, 19.23] |
| 12 Adverse effects: 4a. Other adverse events |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 12.1 dizziness ‐ short term (up to 12 weeks) |
1 |
24 |
Risk Ratio (M‐H, Random, 95% CI) |
1.0 [0.07, 14.21] |
| 12.2 increased appetite ‐ short term (up to 12 weeks) |
1 |
24 |
Risk Ratio (M‐H, Random, 95% CI) |
0.67 [0.13, 3.30] |
| 12.3 orthostasis ‐ short term (up to 12 weeks) |
1 |
24 |
Risk Ratio (M‐H, Random, 95% CI) |
2.0 [0.21, 19.23] |
| 12.4 urinary frequency ‐ short term (up to 12 weeks) |
1 |
24 |
Risk Ratio (M‐H, Random, 95% CI) |
0.33 [0.01, 7.45] |
| 13 Adverse effects: 4b. Other ‐ average endpoint weight loss (average weight in kg) (skewed) |
|
|
Other data |
No numeric data |
| 13.2 short term (up to 12 weeks) |
|
|
Other data |
No numeric data |
| 14 Leaving the study early |
1 |
|
Risk Ratio (IV, Random, 95% CI) |
Subtotals only |
| 14.1 inefficacy ‐ short term (up to 12 weeks) |
1 |
25 |
Risk Ratio (IV, Random, 95% CI) |
0.46 [0.05, 4.46] |
| 14.2 adverse effects ‐ short term (up to 12 weeks) |
1 |
25 |
Risk Ratio (IV, Random, 95% CI) |
0.19 [0.01, 3.52] |
